

**Supplementary Table S6.** Cycle 1 pharmacokinetic parameters of MOXR0916; mean (standard deviation)

<b>Dose (mg)<sup>a</sup></b>	<b>C<sub>max</sub></b>	<b>AUC<sub>last</sub></b>	<b>CL</b>	<b>V<sub>ss</sub></b>	<b>t<sub>1/2</sub></b>
<b>0.2 (n=3)</b>	0.210 (18.7)	NA	NA	NA	NA
<b>0.8 (n=3)</b>	0.785 (16.4)	1.02 (77.3)	1.11 (NA)	5.00 (NA)	3.12 (NA)
<b>3.2 (n=6)</b>	3.03 (22.2)	19.3 (42.7)	0.589 (52.2)	4.38 (20.9)	5.95 (32.8)
<b>12 (n=11)</b>	8.82 (24.7)	70.5 (50.2)	0.410 (45.4)	6.17 (36.8)	11.1 (28.5)
<b>40 (n=7)</b>	23.5 (23.4)	198 (30.3)	0.332 (39.3)	4.99 (25.2)	11.3 (18.6)
<b>80 (n=12)</b>	42.2 (20.3)	375 (30.8)	0.332 (60.4)	5.43 (17.2)	15.2 (49.1)
<b>160 (n=11)</b>	81.4 (28.4)	716 (42.1)	0.295 (44.6)	5.46 (28.4)	15.7 (67.1)
<b>300 (n=107)</b>	196 (17.7)	1780 (38.2)	0.214 (83.1)	4.87 (25.3)	22.1 (40.9)
<b>600 (n=6)</b>	328 (28.5)	2963 (28.7)	0.270 (41.9)	5.78 (9.4)	18.7 (60.3)
<b>1200 (n=4)</b>	0.210 (18.7)	NA	NA	NA	NA

<sup>a</sup>The majority of samples for patients who received 0.2 and 0.8 mg were below the assay lower limit of quantification